» Articles » PMID: 16049050

Levels of Matrix Metalloproteinase (MMP)-1 in Paired Sera and Synovial Fluids of Juvenile Idiopathic Arthritis Patients: Relationship to Inflammatory Activity, MMP-3 and Tissue Inhibitor of Metalloproteinases-1 in a Longitudinal Study

Overview
Specialty Rheumatology
Date 2005 Jul 29
PMID 16049050
Citations 26
Authors
Affiliations
Soon will be listed here.
Abstract

Objectives: To measure levels of the collagenases matrix metalloproteinase (MMP)-1 and -13 in the synovial fluid (SF) and serum of patients with juvenile idiopathic arthritis (JIA), and to correlate these measurements with inflammatory activity, levels of the collagenase activator MMP-3 and the tissue inhibitor of metalloproteinases-1 (TIMP-1).

Methods: Levels of MMP-1, -3, -13 and TIMP-1 were measured in paired SF and serum from 82 JIA patients using enzyme-linked immunsorbent assay and compared between subtypes and patients of different ages and disease durations. These levels were also correlated to the active joint count (AJC) and standard measures of inflammatory activity and therapeutic response, including erythrocyte sedimentation rate (ESR) and platelet count (PLT).

Results: MMP-1 was detected in JIA SF and correlated with PLT. MMP-3 levels were high in SF and detectable in serum where they correlated with PLT, ESR and AJC. MMP-13, however, was not detected in SF or serum. No differences were observed between patients grouped by subtype, age or disease duration. MMP-3 contributed the majority of total MMP in SF samples resulting in excess MMP levels over TIMP-1.

Conclusions: MMP-1 is up-regulated in SF concordant with inflammatory activity in JIA. This was true for patients in all JIA subtypes and age groups, suggesting that the capability for degradation of type II collagen is present in early disease, and throughout the disease course. MMP-3 may be important in the activation of collagenases and the saturation of exogenous inhibitors. Serum MMP-3 may therefore be a useful, measurable and specific marker of active disease in JIA.

Citing Articles

Serum CS/DS, IGF-1, and IGFBP-3 as Biomarkers of Cartilage Remodeling in Juvenile Idiopathic Arthritis: Diagnostic and Therapeutic Implications.

Winsz-Szczotka K, Kuznik-Trocha K, Kozma E, Zeglen B, Gruenpeter A, Wisowski G Biomolecules. 2025; 14(12.

PMID: 39766233 PMC: 11673752. DOI: 10.3390/biom14121526.


Extensive study of CCN4, VCAM-1, MMP-3, and GM-CSF as reliable markers for disease activity in rheumatoid arthritis.

Yasin A, Ali E, Shari F, Mohammed A J Taibah Univ Med Sci. 2024; 19(4):885-900.

PMID: 39262670 PMC: 11387248. DOI: 10.1016/j.jtumed.2024.08.001.


The Mutational and Microenvironmental Landscape of Cutaneous Squamous Cell Carcinoma: A Review.

Hosseini T, Park S, Guo T Cancers (Basel). 2024; 16(16).

PMID: 39199674 PMC: 11352924. DOI: 10.3390/cancers16162904.


Inflammatory diseases causing joint and bone destruction: rheumatoid arthritis and hemophilic arthropathy.

Terashima A, Ono K, Omata Y, Tanaka S, Saito T J Bone Miner Metab. 2024; 42(4):455-462.

PMID: 38856919 PMC: 11415468. DOI: 10.1007/s00774-024-01520-8.


Co-Delivery of Aceclofenac and Methotrexate Nanoparticles Presents an Effective Treatment for Rheumatoid Arthritis.

Negi S, Tandel N, Garg N, Sharma P, Kumar R, Sharma P Int J Nanomedicine. 2024; 19:2149-2177.

PMID: 38482519 PMC: 10933537. DOI: 10.2147/IJN.S439359.